China's Pharma Companies Face Fiscal Challenges for R&D Projects
China's Pharma Companies Face Fiscal Challenges for R&D Projects
Attachment: China RD pharma 0621
BEIJING--June 8, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--In the last 10 years, the average return on investment (ROI) in China's pharmaceutical research and development (R&D) market has declined, which creates an obstacle for China's small- and medium-sized developers of patterned drugs.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects